Download PDF
Semin Thromb Hemost 2009; 35(7): 613-620
DOI: 10.1055/s-0029-1242715
© Thieme Medical Publishers

Polycystic Ovarian Syndrome and the Risk of Cardiovascular Disease and Thrombosis

Winifred Mak1 , Anuja Dokras1
  • 1Penn Fertility Care, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
09 December 2009 (online)

    Permissions and Reprints

ABSTRACT

Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with multiple comorbidities such as diabetes, dyslipidemia, hypertension, and metabolic syndrome, all of which predispose women with PCOS to early atherosclerosis. Women with PCOS also have a higher prevalence of subclinical atherosclerosis, as reflected in dysregulation of endothelial function, increased carotid intimal-medial thickness, and presence of coronary artery calcification. Preliminary data indicate that serum biomarkers of cardiovascular disease such as high-sensitivity C-reactive protein, homocysteine, and adiponectin are abnormal in women with PCOS. There is limited data on abnormalities in the coagulation and fibrinolytic systems, however. The risk of venous thrombosis is unclear in the PCOS population, and further studies are urgently required to address whether first-line treatment for PCOS with oral contraceptive pills is advisable.

KEYWORDS

Polycystic ovary syndrome - cardiovascular disease - thrombosis - review

REFERENCES

  • 1 Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.  J Clin Endocrinol Metab. 1998;  83(9) 3078-3082
    CrossrefPubMedGoogle Scholar
  • 2 Asunción M, Calvo R M, San Millán J L, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.  J Clin Endocrinol Metab. 2000;  85(7) 2434-2438
    CrossrefPubMedGoogle Scholar
  • 3 Diamanti-Kandarakis E, Kouli C R, Bergiele A T et al.. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.  J Clin Endocrinol Metab. 1999;  84(11) 4006-4011
    CrossrefPubMedGoogle Scholar
  • 4 Rotterdam ESHRE/ASRM – Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.  Fertil Steril. 2004;  81(1) 19-25
    PubMedGoogle Scholar
  • 5 Azziz R, Carmina E, Dewailly D Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.  Fertil Steril. 2009;  91(2) 456-488
    CrossrefPubMedGoogle Scholar
  • 6 Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome.  Hum Reprod. 2001;  16(6) 1255-1260
    CrossrefPubMedGoogle Scholar
  • 7 Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?.  Hum Reprod. 1996;  11(1) 23-28
    PubMedGoogle Scholar
  • 8 Chobanian A V, Bakris G L, Black H R National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.  JAMA. 2003;  289(19) 2560-2572
    CrossrefPubMedGoogle Scholar
  • 9 Lo J C, Feigenbaum S L, Yang J, Pressman A R, Selby J V, Go A S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.  J Clin Endocrinol Metab. 2006;  91(4) 1357-1363
    CrossrefPubMedGoogle Scholar
  • 10 Chen M J, Yang W S, Yang J H, Chen C L, Ho H N, Yang Y S. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.  Hypertension. 2007;  49(6) 1442-1447
    CrossrefPubMedGoogle Scholar
  • 11 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84(1) 165-169
    CrossrefPubMedGoogle Scholar
  • 12 Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome.  Int J Gynaecol Obstet. 2001;  75(2) 177-184
    CrossrefPubMedGoogle Scholar
  • 13 Gambineri A, Pelusi C, Manicardi E et al.. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors.  Diabetes. 2004;  53(9) 2353-2358
    CrossrefPubMedGoogle Scholar
  • 14 Ehrmann D A, Kasza K, Azziz R, Legro R S, Ghazzi M N. PCOS/Troglitazone Study Group . Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90(1) 66-71
    Google Scholar
  • 15 Legro R S, Gnatuk C L, Kunselman A R, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study.  J Clin Endocrinol Metab. 2005;  90(6) 3236-3242
    CrossrefPubMedGoogle Scholar
  • 16 Goldberg R B, Temprosa M, Haffner S Diabetes Prevention Program Research Group et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.  Diabetes Care. 2009;  32(4) 726-732
    CrossrefPubMedGoogle Scholar
  • 17 Legro R S, Kunselman A R, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.  Am J Med. 2001;  111(8) 607-613
    CrossrefPubMedGoogle Scholar
  • 18 Wild R A, Painter P C, Coulson P B, Carruth K B, Ranney G B. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1985;  61(5) 946-951
    CrossrefPubMedGoogle Scholar
  • 19 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.  Circulation. 2002;  106(25) 3143-3421
    PubMedGoogle Scholar
  • 20 Dejager S, Pichard C, Giral P et al.. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls.  Clin Endocrinol (Oxf). 2001;  54(4) 455-462
    CrossrefPubMedGoogle Scholar
  • 21 Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2007;  92(1) 186-189
    CrossrefPubMedGoogle Scholar
  • 22 McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant.  Ann Intern Med. 2003;  139(10) 802-809
    PubMedGoogle Scholar
  • 23 Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity.  Clin Chem. 2004;  50(12) 2316-2322
    CrossrefPubMedGoogle Scholar
  • 24 Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia D H. Screening women with polycystic ovary syndrome for metabolic syndrome.  Obstet Gynecol. 2005;  106(1) 131-137
    Google Scholar
  • 25 McLaughlin T, Reaven G, Abbasi F et al.. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?.  Am J Cardiol. 2005;  96(3) 399-404
    CrossrefPubMedGoogle Scholar
  • 26 Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age.  Clin Chem. 1990;  36(1) 20-23
    PubMedGoogle Scholar
  • 27 Nagayama M, Shinohara Y, Nagayama T. Lipoprotein(a) and ischemic cerebrovascular disease in young adults.  Stroke. 1994;  25(1) 74-78
    PubMedGoogle Scholar
  • 28 Bostom A G, Cupples L A, Jenner J L et al.. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study.  JAMA. 1996;  276(7) 544-548
    CrossrefPubMedGoogle Scholar
  • 29 Berneis K, Rizzo M, Hersberger M et al.. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.  Int J Clin Pract. 2009;  63(1) 56-62
    CrossrefPubMedGoogle Scholar
  • 30 Yilmaz M, Biri A, Bukan N et al.. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.  Gynecol Endocrinol. 2005;  20(5) 258-263
    CrossrefPubMedGoogle Scholar
  • 31 Andiran N, Yordam N. Lipoprotein(a) levels in girls with premature adrenarche.  J Paediatr Child Health. 2008;  44(3) 138-142
    CrossrefPubMedGoogle Scholar
  • 32 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA. 2001;  285(19) 2486-2497
    CrossrefPubMedGoogle Scholar
  • 33 Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. DECODE Study Group . Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.  Arch Intern Med. 2004;  164(10) 1066-1076
    CrossrefPubMedGoogle Scholar
  • 34 Talbott E O, Zborowski J V, Rager J R, Boudreaux M Y, Edmundowicz D A, Guzick D S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89(11) 5454-5461
    CrossrefPubMedGoogle Scholar
  • 35 Ehrmann D A, Liljenquist D R, Kasza K, Azziz R, Legro R S, Ghazzi M N. PCOS/Troglitazone Study Group . Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2006;  91(1) 48-53
    CrossrefPubMedGoogle Scholar
  • 36 Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease.  Circulation. 2001;  104(22) 2673-2678
    CrossrefPubMedGoogle Scholar
  • 37 Perticone F, Ceravolo R, Pujia A et al.. Prognostic significance of endothelial dysfunction in hypertensive patients.  Circulation. 2001;  104(2) 191-196
    PubMedGoogle Scholar
  • 38 Steinberg H O, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.  J Clin Invest. 1996;  97(11) 2601-2610
    CrossrefPubMedGoogle Scholar
  • 39 Orio Jr F, Palomba S, Cascella T et al.. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89(9) 4588-4593
    CrossrefPubMedGoogle Scholar
  • 40 Tarkun I, Arslan B C, Cantürk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.  J Clin Endocrinol Metab. 2004;  89(11) 5592-5596
    CrossrefPubMedGoogle Scholar
  • 41 Dokras A, Jagasia D H, Maifeld M, Sinkey C A, VanVoorhis B J, Haynes W G. Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome.  Fertil Steril. 2006;  86(6) 1702-1709
    CrossrefPubMedGoogle Scholar
  • 42 Paradisi G, Steinberg H O, Hempfling A et al.. Polycystic ovary syndrome is associated with endothelial dysfunction.  Circulation. 2001;  103(10) 1410-1415
    CrossrefPubMedGoogle Scholar
  • 43 Mather K J, Verma S, Corenblum B, Anderson T J. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2000;  85(5) 1851-1856
    CrossrefPubMedGoogle Scholar
  • 44 Bickerton A S, Clark N, Meeking D et al.. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS).  J Clin Pathol. 2005;  58(2) 151-154
    CrossrefPubMedGoogle Scholar
  • 45 Moran L J, Hutchison S K, Meyer C, Zoungas S, Teede H J. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.  Clin Sci (Lond). 2009;  116(10) 761-770
    CrossrefPubMedGoogle Scholar
  • 46 Bots M L, Baldassarre D, Simon A et al.. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations?.  Eur Heart J. 2007;  28(4) 398-406
    CrossrefPubMedGoogle Scholar
  • 47 Talbott E O, Guzick D S, Sutton-Tyrrell K et al.. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.  Arterioscler Thromb Vasc Biol. 2000;  20(11) 2414-2421
    PubMedGoogle Scholar
  • 48 Carmina E, Orio F, Palomba S et al.. Endothelial dysfunction in PCOS: role of obesity and adipose hormones.  Am J Med. 2006;  119(4) 356.e1-6
    PubMedGoogle Scholar
  • 49 Agatston A S, Janowitz W R, Hildner F J, Zusmer N R, Viamonte Jr M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography.  J Am Coll Cardiol. 1990;  15(4) 827-832
    CrossrefPubMedGoogle Scholar
  • 50 Arad Y, Spadaro L A, Goodman K, Newstein D, Guerci A D. Prediction of coronary events with electron beam computed tomography.  J Am Coll Cardiol. 2000;  36(4) 1253-1260
    CrossrefPubMedGoogle Scholar
  • 51 Christian R C, Dumesic D A, Behrenbeck T, Oberg A L, Sheedy II P F, Fitzpatrick L A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88(6) 2562-2568
    CrossrefPubMedGoogle Scholar
  • 52 Shroff R, Kerchner A, Maifeld M, Van Beek E J, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.  J Clin Endocrinol Metab. 2007;  92(12) 4609-4614
    CrossrefPubMedGoogle Scholar
  • 53 Mahoney L T, Burns T L, Stanford W et al.. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study.  J Am Coll Cardiol. 1996;  27(2) 277-284
    PubMedGoogle Scholar
  • 54 Tsimikas S, Willerson J T, Ridker P M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.  J Am Coll Cardiol. 2006;  47(8, Suppl) C19-C31
    CrossrefPubMedGoogle Scholar
  • 55 Kelly C C, Lyall H, Petrie J R, Gould G W, Connell J M, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome.  J Clin Endocrinol Metab. 2001;  86(6) 2453-2455
    CrossrefPubMedGoogle Scholar
  • 56 Boulman N, Levy Y, Leiba R et al.. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease.  J Clin Endocrinol Metab. 2004;  89(5) 2160-2165
    CrossrefPubMedGoogle Scholar
  • 57 Möhlig M, Spranger J, Osterhoff M et al.. The polycystic ovary syndrome per se is not associated with increased chronic inflammation.  Eur J Endocrinol. 2004;  150(4) 525-532
    CrossrefPubMedGoogle Scholar
  • 58 Stampfer M J, Malinow M R, Willett W C et al.. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.  JAMA. 1992;  268(7) 877-881
    CrossrefPubMedGoogle Scholar
  • 59 Arnesen E, Refsum H, Bønaa K H, Ueland P M, Førde O H, Nordrehaug J E. Serum total homocysteine and coronary heart disease.  Int J Epidemiol. 1995;  24(4) 704-709
    CrossrefPubMedGoogle Scholar
  • 60 Welch G N, Loscalzo J. Homocysteine and atherothrombosis.  N Engl J Med. 1998;  338(15) 1042-1050
    Google Scholar
  • 61 McCarty M F. Insulin secretion as a potential determinant of homocysteine levels.  Med Hypotheses. 2000;  55(5) 454-455
    CrossrefPubMedGoogle Scholar
  • 62 Giltay E J, Hoogeveen E K, Elbers J M, Gooren L J, Asscheman H, Stehouwer C D. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects.  Atherosclerosis. 1998;  139(1) 197-198
    CrossrefPubMedGoogle Scholar
  • 63 Yarali H, Yildirir A, Aybar F et al.. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.  Fertil Steril. 2001;  76(3) 511-516
    CrossrefPubMedGoogle Scholar
  • 64 Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome.  Gynecol Obstet Invest. 2002;  53(3) 157-162
    CrossrefPubMedGoogle Scholar
  • 65 Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine.  Hum Reprod. 2003;  18(4) 721-727
    CrossrefPubMedGoogle Scholar
  • 66 Badawy A, State O, El Gawad SSh, El Aziz O A. Plasma homocysteine and polycystic ovary syndrome: the missed link.  Eur J Obstet Gynecol Reprod Biol. 2007;  131(1) 68-72
    CrossrefPubMedGoogle Scholar
  • 67 Weyer C, Funahashi T, Tanaka S et al.. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86(5) 1930-1935
    CrossrefPubMedGoogle Scholar
  • 68 Jalovaara K, Santaniemi M, Timonen M et al.. Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population.  Metabolism. 2008;  57(8) 1130-1134
    CrossrefPubMedGoogle Scholar
  • 69 Zyriax B C, Algenstaedt P, Hess U F et al.. Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study.  Atherosclerosis. 2008;  200(2) 403-409
    CrossrefPubMedGoogle Scholar
  • 70 Toulis K A, Goulis D G, Farmakiotis D et al.. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis.  Hum Reprod Update. 2009;  15(3) 297-307
    CrossrefPubMedGoogle Scholar
  • 71 Carmassi F, De Negri F, Fioriti R et al.. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.  Thromb Res. 2005;  116(3) 207-214
    CrossrefPubMedGoogle Scholar
  • 72 Orio Jr F, Palomba S, Cascella T et al.. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?.  Reprod Biomed Online. 2004;  9(5) 505-510
    CrossrefPubMedGoogle Scholar
  • 73 Carmassi F, Morale M, Ferrini L et al.. Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects.  Am J Med. 1999;  107(4) 344-350
    CrossrefPubMedGoogle Scholar
  • 74 Atiomo W U, Fox R, Condon J E et al.. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).  Clin Endocrinol (Oxf). 2000;  52(4) 487-492
    CrossrefPubMedGoogle Scholar
  • 75 Atiomo W U, Condon J, Adekanmi O, Friend J, Wilkin T J, Prentice A G. Are women with polycystic ovary syndrome resistant to activated protein C?.  Fertil Steril. 2000;  74(6) 1229-1232
    CrossrefPubMedGoogle Scholar
  • 76 Tsanadis G, Vartholomatos G, Korkontzelos I et al.. Polycystic ovarian syndrome and thrombophilia.  Hum Reprod. 2002;  17(2) 314-319
    CrossrefPubMedGoogle Scholar
  • 77 Yildiz B O, Haznedaroğlu I C, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state.  J Clin Endocrinol Metab. 2002;  87(8) 3871-3875
    CrossrefPubMedGoogle Scholar
  • 78 Ay C, Tengler T, Vormittag R et al.. Venous thromboembolism—a manifestation of the metabolic syndrome.  Haematologica. 2007;  92(3) 374-380
    CrossrefPubMedGoogle Scholar
  • 79 Dahlgren E, Janson P O, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women.  Acta Obstet Gynecol Scand. 1992;  71(8) 599-604
    CrossrefPubMedGoogle Scholar
  • 80 Birdsall M A, Farquhar C M, White H D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization.  Ann Intern Med. 1997;  126(1) 32-35
    CrossrefPubMedGoogle Scholar
  • 81 Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.  Clin Endocrinol (Oxf). 2000;  52(5) 595-600
    Google Scholar
  • 82 Solomon C G, Hu F B, Dunaif A et al.. Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87(5) 2013-2017
    CrossrefPubMedGoogle Scholar
  • 83 Shaw L J, Bairey Merz C N, Azziz R et al.. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.  J Clin Endocrinol Metab. 2008;  93(4) 1276-1284
    CrossrefPubMedGoogle Scholar

Anuja DokrasM.D. Ph.D. 

Penn Fertility Care, University of Pennsylvania Medical Center

3701 Market Street, Suite 800, Philadelphia PA 19104

Email: adokras@obgyn.upenn.edu